Bisfosfonaatgerelateerde osteonecrose van de kaak 1.

Translated title of the contribution: Bisphosphonate-associated osteonecrosis of the jaws 1

R. H. Allard*, P. Lips, E. M. Eekhoff, J. P. van Merkesteyn, I. van der Waal

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Bisphosphonates are generally administered either orally or intravenously. Orally administered bisphosphonates are primarilly used in the treatment of postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, and Paget's disease. When orally administered, only about 1% is absorbed from the tractus from the tractus digestivus. With intravenous administration, higher blood levels levels are reached. Intravenously administered bisphosphonates are used in the treatment of hypercalcaemia, Kahler's disease, and bone metastases of other malignancies. A few cases of osteonecrosis of the jaw(s) are seen especially when more powerful bisphosphonates are administered intravenously. This osteonecrosis is most often provoked by means of an invasive oral treatment. Bisphosphonate-associated osteonecrosis is very difficult to treat. Therefore, dental preventive measures and treatment of dental foci and other inflammations are recommended before starting bisphosphonate therapy.

Translated title of the contributionBisphosphonate-associated osteonecrosis of the jaws 1
Original languageDutch
Pages (from-to)423-427
Number of pages5
JournalNederlands Tijdschrift voor Tandheelkunde
Volume114
Issue number10
Publication statusPublished - Oct 2007

Cite this